📣 VC round data is live. Check it out!

Schrödinger Valuation Multiples

Discover Schrödinger's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth and more.

Schrödinger Overview

About Schrödinger

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.


Founded

1995

HQ

United States

Employees

850

Financials (LTM)

Revenue: $247M
EBITDA: ($140M)

EV

$824M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Schrödinger Financials

Schrödinger reported last 12-month revenue of $247M and negative EBITDA of ($140M).

In the same LTM period, Schrödinger generated $133M in gross profit, ($140M) in EBITDA losses, and had net loss of ($126M).

Revenue (LTM)


Schrödinger P&L

In the most recent fiscal year, Schrödinger reported revenue of $256M and EBITDA of ($139M).

Schrödinger is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (54%), and net margin of (40%).

See analyst estimates for Schrödinger
LTMLast FY202320242025202620272028
Revenue$247M$256M$217M$208M$256M
Gross Profit$133M$143M$141M$132M$143M
Gross Margin54%56%65%64%56%
EBITDA($140M)($139M)($172M)($203M)($161M)
EBITDA Margin(57%)(54%)(79%)(98%)(63%)
EBIT Margin(67%)(65%)(82%)(101%)(65%)
Net Profit($126M)($103M)$41M($187M)($103M)
Net Margin(51%)(40%)19%(90%)(40%)

Financial data powered by Morningstar, Inc.

Schrödinger Stock Performance

Schrödinger has current market cap of $1B, and enterprise value of $824M.

Market Cap Evolution


Schrödinger's stock price is $14.94.

Schrödinger share price decreased by 1.7% in the last 30 days, and by 25.7% in the last year.

Schrödinger has an EPS (earnings per share) of $-1.38.

See more trading valuation data for Schrödinger
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$824M$1B-5.5%-1.7%31.5%-25.7%$-1.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Schrödinger Valuation Multiples

Schrödinger trades at 3.3x EV/Revenue multiple, and (5.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Schrödinger

EV / Revenue (LTM)


Schrödinger Financial Valuation Multiples

As of June 4, 2026, Schrödinger has market cap of $1B and EV of $824M.

Schrödinger has a P/E ratio of (8.8x).

LTMLast FY202320242025202620272028
EV/Revenue3.3x3.2x3.8x4.0x3.2x
EV/EBITDA(5.9x)(5.9x)(4.8x)(4.1x)(5.1x)
EV/EBIT(5.0x)(4.9x)(4.6x)(3.9x)(4.9x)
EV/Gross Profit6.2x5.8x5.9x6.2x5.8x
P/E(8.8x)(10.8x)27.4x(6.0x)(10.8x)
EV/FCF-66.2x(5.5x)(5.0x)66.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Schrödinger Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Schrödinger Margins & Growth Rates

Schrödinger decreased revenue by 8% but EBITDA grew by 2% in the last fiscal year.

In the most recent fiscal year, Schrödinger reported gross margin of 56%, EBITDA margin of (54%), and net margin of (40%).

See estimated margins and future growth rates for Schrödinger

Schrödinger Margins

Last FY202420252026202720282029
Gross Margin56%64%56%51%
EBITDA Margin(54%)(98%)(63%)(60%)
EBIT Margin(65%)(101%)(65%)(69%)
Net Margin(40%)(90%)(40%)(67%)
FCF Margin5%(79%)5%-

Schrödinger Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(8%)(4%)23%(8%)
Gross Profit Growth(16%)(6%)8%(16%)
EBITDA Growth2%18%(21%)(12%)
EBIT Growth(3%)18%(20%)(3%)
Net Profit Growth53%(560%)(45%)53%
FCF Growth-10%(108%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Schrödinger Operational KPIs

Schrödinger's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Schrödinger's Rule of 40 is (69%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Schrödinger's Rule of X is (81%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Schrödinger
LTMLast FY202320242025202620272028
Rule of 40(57%)(69%)---
Bessemer Rule of X(56%)(81%)---
Revenue per Employee-$0.3M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue17%16%17%19%16%
G&A Expenses to Revenue37%37%46%48%37%
R&D Expenses to Revenue68%68%84%97%68%
Opex to Revenue-121%147%164%121%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Schrödinger Competitors

Schrödinger competitors include Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth, U.S. Physical Therapy, Hangzhou Pinming Software, Indegene, B-Soft Co., PHC Holdings and RaySearch Labs.

Most Schrödinger public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vitec Software3.6x3.5x9.2x9.5x
Sphere19.2x-201.2x-
MedicalSystem Technology21.4x19.2x72.6x83.5x
iFLYHealth9.3x8.3x(240.0x)(233.9x)
U.S. Physical Therapy1.6x1.6x11.7x13.0x
Hangzhou Pinming Software14.1x-110.1x-
Indegene3.1x3.0x16.6x17.0x
B-Soft Co.5.5x5.3x(24.2x)(51.4x)

This data is available for Pro users. Sign up to see all Schrödinger competitors and their valuation data.

Start Free Trial

Schrödinger VC Funding History

Before going public, Schrödinger raised $155M in total equity funding, across 3 rounds.


Schrödinger Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-19Series EFormic Ventures; Invus; Laurion Capital Management; Michael Antonov; Pavilion Capital Partners; Sixty Degree Capital$25M-Schrödinger, a leading provider of advanced molecular simulations and enterprise software for drug discovery and materials design, announced the close of its latest funding round on May 19, 2019, raising a total of $110 million. New investors in the round included Invus, Pavilion Capital Partners, Oculus co-founder Michael Antonov via his Tubus Management fund, Laurion Capital Management, Formic Ventures, and Sixty Degree Capital, joining prior investors such as the Bill and Melinda Gates Foundation Trust, WuXi AppTec’s Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV. The funding was intended to support advancements in the company’s computational platform and expansion of its proprietary therapeutic pipeline. Founded in 1990, Schrödinger had nearly 400 employees across the US, Europe, Japan, and India, with partners in China and Korea. The company had validated its platform across hundreds of drug discovery targets, co-founded biotechs like Nimbus Therapeutics and Morphic Therapeutic, and maintained deep collaborations in biotech, pharma, chemicals, and electronics. The company went public in February 2020, raising $232.3 million at $17 per share on Nasdaq under SDGR.
Jan-19Series EBaron Capital Management; Bill & Melinda Gates Foundation; Deerfield; GV; Qiming Venture Partners; Wuxi AppTec$108M-Schrödinger is a physics-based platform provider for drug discovery and advanced materials, offering computational software that accelerates molecular simulations and enterprise solutions for pharmaceuticals, biotechnology, chemicals, and electronics. The company announced the close of its latest financing round on May 19, 2019, raising a total of $110 million from new investors including Bill & Melinda Gates Foundation and Wuxi AppTec, along with Baron Capital Management, Deerfield, GV, and Qiming Venture Partners. The funding supports advancements in Schrödinger’s computational platform and expansion of its wholly-owned therapeutic drug discovery pipeline, as well as continued collaborations with biopharma companies worldwide. These partnerships have resulted in two FDA-approved oncology drugs, several clinical-stage assets, and over two dozen programs in discovery and development. CEO Ramy Farid emphasized the platform's validation across hundreds of targets in real-world projects. Schrödinger had nearly 400 employees at the time, with operations in the US, Europe, Japan, and India, plus partners in China and Korea. The company has cofounded biotechs like Nimbus Therapeutics and Morphic Therapeutic.
Jun-15Series DBill & Melinda Gates Foundation; Scott Becker$22M--

Acquisitions by Schrödinger

Schrödinger has acquired 1 company to date.

Last acquisition by Schrödinger was on January 18th 2022. Schrödinger acquired Xtal BioStructures for $6M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Schrödinger

Xtal BioStructures
Description
Xtal BioStructures is a Markhams-based provider of biopharmaceutical protein services including crystallization, structure determination, and purification. The company supports drug discovery efforts with X-ray crystallography, synchrotron beamline access, and recombinant protein production for clients in oncology and infectious disease research.
HQ CountryUnited States
HQ City
Boston, MA
Deal Date18 Jan 2022
Valuation$6M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Schrödinger acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Schrödinger

Schrödinger has invested in 3 companies to date.

Latest investment by Schrödinger was on May 13th 2024. Schrödinger invested in Ajax Therapeutics in their $95M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Schrödinger

Ajax Therapeutics
Ajax Therapeutics
Morphic Therapeutic
Nimbus Therapeutics
Description
Ajax Therapeutics is a New York City-based biotechnology company that employs computational chemistry and structure-based design to create small molecule inhibitors for hematologic malignancies. The firm targets mutated kinases driving myeloproliferative neoplasms, with its lead candidate in Phase 1 trials. Ajax Therapeutics collaborates with Bristol Myers Squibb and maintains a pipeline addressing sickle cell disease.
Ajax Therapeutics is a New York City-based biotechnology company that employs computational chemistry and structure-based design to create small molecule inhibitors for hematologic malignancies. The firm targets mutated kinases driving myeloproliferative neoplasms, with its lead candidate in Phase 1 trials. Ajax Therapeutics collaborates with Bristol Myers Squibb and maintains a pipeline addressing sickle cell disease.
Morphic Therapeutic is a NASDAQ-listed biotechnology company developing oral small-molecule integrin inhibitors for autoimmune diseases, fibrosis, cancer, and cardiovascular conditions. Headquartered in Waltham, Massachusetts, since 2014, it advances MMPD2 inhibitors through Phase 2 trials for inflammatory bowel disease, partnering with Roche for co-development.
Nimbus Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing small molecule therapeutics for metabolic diseases, cancer, and immune-inflammatory disorders. The firm uses computational design for highly selective inhibitors, with a pipeline including clinical candidates in immunology partnered with Celgene.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
-
-
Boston, MA
Boston, MA
Deal Date13 May 20241 Jun 202125 Sep 20185 Jun 2018
RoundSeries CUndisclosed stageSeries BSeries C
Raised$95M$40M$80M$65M
InvestorsBoxer Capital; EcoR1 Capital; Eli Lilly & Company Foundation; Goldman Sachs Asset Management; Inning One Ventures; Point72 Ventures; RA Capital Management; Schrödinger; Vivo CapitalBoxer Capital; EcoR1 Capital; Inning One Ventures; Memorial Sloan Kettering Cancer Center; NYU Langone Health; SchrödingerEcoR1 Capital; Invus; Novo Holdings; Omega Funds; Pfizer Venture Investments; Polaris Partners; Schrödinger; ShangPharma; SR One; Timothy A. SpringerAtlas Venture; Bill Gates; Lightstone Ventures; Lilly Ventures; Pfizer Venture Investments; Schrödinger; SR One
Valuation$193Mundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Schrödinger investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Schrödinger

When was Schrödinger founded?Schrödinger was founded in 1995.
Where is Schrödinger headquartered?Schrödinger is headquartered in United States.
How many employees does Schrödinger have?As of today, Schrödinger has over 850 employees.
Who is the CEO of Schrödinger?Schrödinger's CEO is Ramy Farid.
Is Schrödinger publicly listed?Yes, Schrödinger is a public company listed on Nasdaq.
What is the stock symbol of Schrödinger?Schrödinger trades under SDGR ticker.
When did Schrödinger go public?Schrödinger went public in 2020.
Who are competitors of Schrödinger?Schrödinger main competitors include Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth, U.S. Physical Therapy, Hangzhou Pinming Software, Indegene, B-Soft Co., PHC Holdings, RaySearch Labs.
What is the current market cap of Schrödinger?Schrödinger's current market cap is $1B.
What is the current revenue of Schrödinger?Schrödinger's last 12 months revenue is $247M.
What is the current revenue growth of Schrödinger?Schrödinger revenue growth (NTM/LTM) is 0%.
What is the current EV/Revenue multiple of Schrödinger?Current revenue multiple of Schrödinger is 3.3x.
Is Schrödinger profitable?No, Schrödinger is not profitable.
What is the current EBITDA of Schrödinger?Schrödinger has negative EBITDA and is not profitable.
What is Schrödinger's EBITDA margin?Schrödinger's last 12 months EBITDA margin is (57%).
What is the current EV/EBITDA multiple of Schrödinger?Current EBITDA multiple of Schrödinger is (5.9x).
How many companies Schrödinger has acquired to date?As of June 2026, Schrödinger has acquired 1 company.
What was the largest acquisition by Schrödinger?$6M acquisition of Xtal BioStructures on 18th January 2022 was the largest M&A Schrödinger has done to date.
What companies Schrödinger acquired?Schrödinger acquired Xtal BioStructures.
In how many companies Schrödinger has invested to date?As of June 2026, Schrödinger has invested in 3 companies.
What was the last Schrödinger investment?On 13th May 2024 Schrödinger invested in Ajax Therapeutics, participating in a $95M Series C round at $193M valuation, alongside Boxer Capital, EcoR1 Capital, Eli Lilly & Company Foundation, Goldman Sachs Asset Management, Inning One Ventures, Point72 Ventures, RA Capital Management, and Vivo Capital.
In what companies Schrödinger invested in?Schrödinger invested in Ajax Therapeutics, Morphic Therapeutic, and Nimbus Therapeutics.

See public comps similar to Schrödinger

Lists including Schrödinger

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial